dated
financial statements presented on a GAAP basis, the Company has provided
non-GAAP financial information, which is adjusted net income and adjusted
earnings per share, excluding the impact of these items in this release. The
non-GAAP information is not meant to be considered in isolation or as a
substitute for GAAP financials. The non-GAAP financial information provided by
the Company may also differ from non-GAAP information provided by other
companies. A table below provides a reconciliation of the non-GAAP financial
information to the nearest GAAP measure.
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged
in the research, development, production, marketing and sales of
pharmaceutical products in the People's Republic of China. Its operations are
located in Northeast China in an Economic Development Zone in Laiyang City,
Shandong province. Genesis is a pharmaceutical company in China producing
western and Chinese herbal-based medical drugs in tablet, capsule, and granule
form. For more information, visit: http://www.genesispharmaceuticals.com/
Safe Harbor Statement
Certain statements in this press release that are not historical facts are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause the
Company's actual results and financial position to differ materially from
those included within the forward-looking statements. Forward-looking
statements involve risks and uncertainties, including those relating to the
Company's ability to introduce, manufacture and distribute new drugs. Actual
results may differ materially from predicted results, and reported results
should not be
'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related biology technology :1.
Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 20092.
Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area3.
AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences4.
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 20095.
Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program6.
OmegaGenesis Announces Angiogenesis Application Collaboration7.
Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors8.
Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System9.
Cardiogenesis Reports Third Quarter 2008 Results10.
ThermoGenesis Presentation at Rodman & Renshaw Conference11.
Genesis Pharmaceuticals Launches New Corporate Website